Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (121-130 of 169) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, et al.
The Journal of Urology|January 19, 2016
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial CarcinomaAditya Bagrodia, Eugene K Cha, John P Sfakianos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2017
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial CarcinomaMin Yuen Teo, Richard M Bambury, Emily C Zabor, et al.
Cancer|August 9, 2020
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinomaVictor McPherson, Brendan Reardon, Aravind Bhayankara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial CancersMin Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancerGopa Iyer, Hikmat Al-Ahmadie, Nikolaus Schultz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2005
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyRoy S Herbst, Dean F Bajorin, Harry Bleiberg, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct PathogenesisMatthew T Chang, Alexander Penson, Neil B Desai, et al.
Pageof 17

Showing results (121-130 of 169) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, et al.
The Journal of Urology|January 19, 2016
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial CarcinomaAditya Bagrodia, Eugene K Cha, John P Sfakianos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2017
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial CarcinomaMin Yuen Teo, Richard M Bambury, Emily C Zabor, et al.
Cancer|August 9, 2020
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinomaVictor McPherson, Brendan Reardon, Aravind Bhayankara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial CancersMin Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancerGopa Iyer, Hikmat Al-Ahmadie, Nikolaus Schultz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2005
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyRoy S Herbst, Dean F Bajorin, Harry Bleiberg, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct PathogenesisMatthew T Chang, Alexander Penson, Neil B Desai, et al.
Pageof 17